Balancing the interests of patient data protection and medication safety monitoring in a public-private partnership. by Dreyer, NA et al.
Viewpoint
Balancing the Interests of Patient Data Protection and Medication
Safety Monitoring in a Public-Private Partnership
Nancy A Dreyer1; Stella Blackburn2, MBBS; Valerie Hliva3; Shahrul Mt-Isa4; Jonathan Richardson5; Anna
Jamry-Dziurla6; Alison Bourke7; Rebecca Johnson8
1Quintiles Real-World & Late-Phase Research, Scientific Affairs, Cambridge, MA, United States
2Quintiles Real-World & Late-Phase Research, Reading, United Kingdom
3Quintiles Real-World & Late-Phase Research, St. Prex, Switzerland
4School of Public Health, Imperial College London, London, United Kingdom
5Newcastle University, Newcastle upon Tyne, United Kingdom
6Poznan University of Medical Sciences, Poznan, Poland
7Cegedim Strategic Data, London, United Kingdom
8International Alliance of Patients’ Organizations, London, United Kingdom
Corresponding Author:
Nancy A Dreyer
Quintiles Real-World & Late-Phase Research
Scientific Affairs
201 Broadway
5th floor
Cambridge, MA, 02139
United States
Phone: 1 617 715 6810
Fax: 1 617 206 9464
Email: nancy.dreyer@quintiles.com
Abstract
Obtaining data without the intervention of a health care provider represents an opportunity to expand understanding of the safety
of medications used in difficult-to-study situations, like the first trimester of pregnancy when women may not present for medical
care. While it is widely agreed that personal data, and in particular medical data, needs to be protected from unauthorized use,
data protection requirements for population-based studies vary substantially by country. For public-private partnerships, the
complexities are enhanced. The objective of this viewpoint paper is to illustrate the challenges related to data protection based
on our experiences when performing relatively straightforward direct-to-patient noninterventional research via the Internet or
telephone in four European countries. Pregnant women were invited to participate via the Internet or using an automated telephone
response system in Denmark, the Netherlands, Poland, and the United Kingdom. Information was sought on medications, other
factors that may cause birth defects, and pregnancy outcome. Issues relating to legal controllership of data were most problematic;
assuring compliance with data protection requirements took about two years. There were also inconsistencies in the willingness
to accept nonwritten informed consent. Nonetheless, enrollment and data collection have been completed, and analysis is in
progress. Using direct reporting from consumers to study the safety of medicinal products allows researchers to address a myriad
of research questions relating to everyday clinical practice, including treatment heterogeneity in population subgroups not
traditionally included in clinical trials, like pregnant women, children, and the elderly. Nonetheless, there are a variety of
administrative barriers relating to data protection and informed consent, particularly within the structure of a public-private
partnership.
(JMIR Med Inform 2015;3(2):e18)   doi:10.2196/medinform.3937
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Introduction
First Do No Harm
The Declaration of Helsinki extends the ancient medical tenet
of “Primum non nocere”, “first do no harm”, and provides
protection to human subjects of medical research by establishing
ethical principles to ensure that medical research can never take
precedence over the rights and interests of individual research
subjects [1]. While laudable, harm can also occur by
over-zealous interpretation of rules and regulations that
overcomplicate studies, while adding little, or nothing, to the
protection of subjects. The European Union (EU) “EU Data
Protection Directive” by the European Commission (EC)
(European Directive 95/46 EC) was intended to enable personal
data “to flow freely from one Member State to another”, while
safeguarding the fundamental rights of individuals, yet its
implementation into national law has given rise to a myriad of
interpretations, making multi-country studies challenging.
Medication Safety in Pregnancy
Consider, as an example, the importance of understanding which
medications can be safely used during pregnancy, especially
during the first trimester, since some exposures at this time may
have teratogenic potential [2,3]. Inclusion of pregnant women
in preclinical randomized controlled trials is generally
considered unethical due to the unknown risks which may be
posed to the developing fetus, and as such, pregnant patients
are often excluded unless the medicine is specifically for a
pregnancy related condition. Consequently, safety data for
pregnancy outcomes must be collected after licensing via
noninterventional observational studies, which often utilize
pharmacoepidemiologic techniques to analyze large databases,
such as electronic health records to look for rare events such as
specific congenital anomalies. However, these databases may
not contain information about lifestyle and other factors, which
may also affect the outcome of pregnancy, or may not contain
adequate details concerning concomitant risk factors. These
omissions could bias study interpretation. Hence, the
development and testing of alternative methods of data
collection for pharmacovigilance is important.
Here, we describe the legislative challenges in data ownership
and barriers to approval faced by a public-private partnership
in conducting an observational study of self-reported maternal
medication use and pregnancy outcomes.
Our Experiences
Example of Challenges of Data Ownership and
Barriers to Approval
This observational study of direct-to-consumer data collection
on various exposures during pregnancy was conducted through
a public-private partnership known as the
Pharmacoepidemiological Research on Outcomes of
Therapeutics by a European ConsorTium (PROTECT) [4],
which was coordinated by the European Medicines Agency.
The PROTECT project received support from the Innovative
Medicines Initiative (IMI) Joint Undertaking, which included
financial contribution from the EU's Seventh Framework
Programme (FP7/2007-2013) and in-kind contribution from the
European Federation of Pharmaceutical Industries and
Associations. PROTECT consisted of 35 partners including
pharmaceutical companies, academic organizations, national
and international regulatory agencies, patient organizations, and
other interested parties, and the IMI has now extended this
public-private partnership model to address other important
public health concerns [5].
While other PROTECT work packages focused on
methodological challenges using existing data sources, we
explored digital technologies for frequent and timely data
collection from consumers for the purposes of determining
whether this is a viable alternative as a pharmacovigilance tool.
This study was conducted according to the current best practices
for noninterventional drug safety research including full
protocol, specification of analytic methods and data to be
collected, and a description of the plan for protecting human
subjects [6]. Pregnant women were invited to participate via
Internet or using an automated telephone response system
(Interactive Voice Response System). Information was collected
via a secure website from women in Denmark, the Netherlands,
Poland, and the United Kingdom (UK) who identified
themselves as pregnant, and were recruited through websites,
emails, leaflets, television, and social media platforms. Health
care professionals were not involved directly in study
recruitment or promotion. Data were collected on prescription,
nonprescription and herbal medications, recreational drug use,
age, ethnicity, and lifestyle factors. Data were treated with strict
confidential measures; for example, contact details were
key-coded and deleted after the study end, and medical data
were stored on a separate, secure server with restricted physical
and password access. Local academic centers and a national
health system entity served as country study leads, and notified
the local ethics committee and data protection agencies.
Regulatory and data protection submissions were performed
according to the local requirements in the participating countries.
Some Examples of Variations by Country
There was substantial variation in the requirements for ethical
review. Table 1 shows the differences in protocol requirements
and the length of time needed for ethical and data protection
review in each country and by the European Medicines Agency.
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Table 1. Country specific protocol differences; ethical and data protection requirements and timing.
European
Medicines Agency
United KingdomPolandNetherlandsDenmarkProtocol
differences
N/AaNewcastle UniversityPoznan University of Medi-
cal Sciences
University of GroningenStatens Serum InstituteCountry lead
N/Aa16181818Minimum age
(years)
N/AaBoth Internet and
IVRSb possible
Written informed consent
required in addition to Inter-
net and IVRSb informed
consent
Both Internet and IVRSb
possible
Electronic only, IVRSb
not acceptable
Informed consent
N/AaSeparate consent re-
quested
N/AaN/AaRequired for study entryConsent for indi-
vidual record
linkage
N/Aa3 weeks1 weekWaiver (certificate of
nonobjection)
Not requiredEthical approval
timing
3 months opinion,
5 months prior
check
2 weeks9 months1 day~3 monthsTime for
data protection
approval
a N/A=not applicable
b IVRS = Interactive Voice Response system
Some Examples of Variations by Country
Denmark did not require ethical review for an observational
study. In the Netherlands, a waiver (literally, a certification of
nonobjection) was granted since the personal identifiers were
securely retained and maintained separately from study analysis
files. In Poland and the UK, ethics submission required
submitting the study protocol and all study documents (informed
consent, questionnaires, etc) and other administrative
information.
It is also worth noting the differences between countries in
enrollment requirements and informed consent. Although the
study was designed to give the choice of participating by phone
or Internet to facilitate recruitment of low-income women, one
country required all participants to enroll on the Internet before
being able to respond by phone, and another required printing
and mailing written informed consent in addition to consent by
phone or Internet.
Formal notifications were required for data protection. The
European Medicines Agency, as required under Article 27 of
Regulation (EC) number 45/2001, submitted a notification for
prior check with the European Data Protection Supervisor
(EDPS) in October 2010. The EDPS opinion was that, since all
study partners were involved in the development of the protocol
and all could decide on the “means and purposes of the
processing of personal data” and review results, all study
partners effectively determined the purposes of the collection
of the data and were “joint controllers”. As a result of this ruling,
a formal memorandum was prepared detailing each partner’s
role and participation in the study, responsibilities to the study
and other partners, and to data protection. It took about 14
months to get these agreements in place, since they required
agreement from all study partners. After these provisions were
in place, the EDPS confirmed that the processing operations
would not involve any breach of Regulation (EC) No 45/2001.
In the Netherlands, approval of data protection was granted on
the same day the request was submitted, and review was also
relatively quick in the UK and in Denmark. However, review
by the Polish Data Protection Agency took 9 months and
required submission of special items including the characteristics
of the Personal Data Administrator, the technical and
organizational conditions, and how those conditions would be
fulfilled to comply with Polish legislation.
Results
Data collection for this study closed in the first quarter of 2015.
Analyses examining the type of information reported by
respondents are in progress, including comparisons of
self-reported data with that available from electronic medical
records and with the Danish National Prescription Registry.
Analyses will be completed in 2015.
Discussion
Benefits and Challenges of Direct-to-Consumer Health
Research Findings
Using direct reporting from consumers to study the safety of
medicinal products allows researchers to address a myriad of
research questions relating to everyday clinical practice,
including treatment heterogeneity in population subgroups not
traditionally included in clinical trials, like pregnant women,
children, and the elderly. Internet-based studies such as this
may also be useful for studying illicit drug use and other risky
behaviors, since there is some evidence suggesting that patients
will tell computers things that they might not tell health care
professionals [7]. These studies can be supplemented with
clinical validation and pharmacy prescription data, but
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direct-to-patient data collection may provide additional
information about potentially harmful exposures that would not
have been recorded elsewhere, and consequently would not be
available to researchers. Nonetheless, there are a variety of
administrative barriers, including obtaining informed consent
for subjects participating by phone or Internet. The variations
in informed consent requirements encountered here largely
reflect challenges of recruitment without intervention of health
care professionals, and are one of many complexities faced by
Ethics Committees from use of emerging technologies [8].
Added Complexities of Public-Private Partnerships
There were substantial barriers due to the nature of the funding
structure, in addition to the challenges typically encountered in
conducting direct-to-patient medical research. Public-private
partnerships like this IMI project are becoming more prevalent
as desirable funding mechanisms for research on the safety of
medications and medical devices used in everyday clinical
practice, for example, IMI Get Real [9] in Europe and the Food
and Drug Administration’s efforts to build a postmarket National
Medical Device Safety System in the United States [10]. In fact,
at this time, the IMI is Europe's largest public-private initiative
aiming to speed up the development of better and safer
medicines for patients. With these large efforts come tremendous
opportunities, but also substantial additional work relating to
partnership governance, including shared liability. In this study,
for example, assuring compliance with data protection
requirements took about two years, which delayed data
collection, reduced the overall time available for study conduct,
and required substantial investment of legal and administrative
time over and above any traditional research project. Moreover,
most countries did not initially recognize the status of joint
controller, arguing that only two partners had control of personal
data, those who handled data collection and those who
conducted study analyses. The concept that all parties to a
research study must bear the full legal burden of being joint
controllers, which includes accepting responsibility for legal
damages regardless of culpability, needs updating. Fortunately,
in this case all partners agreed to accept joint controller status,
but refusal by one or more partners, or refusal by a country to
accept that a person, agency, or institution had this status and/or
to refuse a notification, could jeopardize other such
collaborations.
The text of the proposed data protection regulation, which was
endorsed by the European Parliament at its first reading in
March 2014, if adopted into law, will do little to improve the
situation [11]. The joint controller status still exists and although
a single “competent” supervisory authority of the EU territory
of the researcher’s main establishment can be requested to
certify that the processing of personal data complies with the
regulation, amendments to the proposed regulation require
cooperation of supervisory authorities from other Member
States. At the same time, supervisory authorities in disagreement
with decisions are allowed the right of appeal to the European
Data Protection Board. Uncertainty remains as to how this
“cooperation” mechanism will operate to give much needed
consistency. Moreover, the proposed regulation allows for
multiple codes of conduct to be developed and approved by the
supervisory authority of individual Member States and/or the
European Commission, once again opening the door for
disharmonized interpretations, now with much higher stakes
since fines relating to failure to comply with the regulation can
be as high as €100 million or 5% of annual worldwide turnover
[11].
Data protection legislation is intended to allow freedom of
movement of data, while protecting people from the theoretical
harm of disclosure of personal data. This theoretical harm of
disclosure of data that could be linked to an individual needs
to be balanced against the potential for actual harm that could
result from failure to identify safety signals in a timely fashion.
Further, issues of data protection which require joint controller
status to be shared among multiple parties may discourage
participation, and might even drive health research away from
regions of most interest to areas with potentially weaker
protection of patient privacy and medication use that is quite
different [4,12]. The potential financial consequences are
considerable for an enterprise and may mean that companies or
institutions may be reluctant to join consortia where the
negligent actions of one partner could have such huge
repercussions on the others, thus weakening the value of the
public-private partnership investment.
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